SMS Finance

Market News

Mesoblast’s Revascor gets FDA nod, but shares dip

Mesoblast (ASX:MSB) has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy designation to its Revascor (rexlemestrocel-L) drug for children with hypoplastic left heart syndrome (HLHS). This builds on earlier FDA designations of Rare Pediatric Disease (RPD) and Orphan-Drug (OD) status for the therapy. Mesoblast develops allogeneic (off-the-shelf) cellular medicines […]

Mesoblast’s Revascor gets FDA nod, but shares dip Read More »

Larvotto Resources secures $30m equity raise

Larvotto Resources (ASX:LRV) has announced a successful $30m equity raising through the placement of 57.7 million new shares at $0.52 each. This two-tranche placement saw strong support from both existing and new institutional investors. The funds, combined with $6.2m from a recently announced antimony prepayment facility and $8m from options conversion, bolster Larvotto’s ability to

Larvotto Resources secures $30m equity raise Read More »

Spartan Resources raises $220m

Spartan Resources (ASX:SPR) has secured $220m in funding through an institutional placement to accelerate the restart of operations at its Dalgaranga Gold Project in Western Australia. The placement, conducted at $1.32 per share, received strong backing from domestic and international resource-focused investors. Notably, Ramelius Resources (ASX:RMS), Spartan’s largest shareholder, increased its stake to 19.9% through

Spartan Resources raises $220m Read More »

INOVIQ completes study for breast cancer test

INOVIQ (ASX:IIQ) has announced progress in breast cancer diagnostics, completing a pivotal study for its “neuCA15-3” blood test. The test is designed to detect breast cancer across all stages and major subtypes. It achieved 81% sensitivity (correctly identifying those with breast cancer) and 93% specificity (accurately excluding those without breast cancer).  INOVIQ is a biotech

INOVIQ completes study for breast cancer test Read More »

HMC Capital (ASX:HMC) acquires Neoen’s Victorian renewable portfolio for $950m

HMC Capital has announced the acquisition of Neoen’s Victorian renewable energy portfolio for $950m, marking a step in its move into the energy transition sector. The portfolio includes 652MW of operational capacity across wind, solar, and battery energy storage systems (BESS), along with a 2.8GW development pipeline featuring advanced-stage projects. The purchase will seed HMC’s

HMC Capital (ASX:HMC) acquires Neoen’s Victorian renewable portfolio for $950m Read More »

Goldilocks stayed for 2024, but what’s in store for investors in 2025?

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses key themes for 2024. Key points The key themes for 2024 were: better than feared growth; global divergence; more disinflation; falling interest rates but with Australia lagging; and more geopolitical threats but not as bad as feared. As in 2023, returns were

Goldilocks stayed for 2024, but what’s in store for investors in 2025? Read More »

DroneShield (ASX:DRO) secures $8.2m European defence contract

DroneShield (ASX:DRO) has announced a repeat order worth $8.2m from a major European military customer. The contract involves providing dismounted and vehicle-mounted counter-drone (Counter-UxS) systems, with delivery expected over the next three months, including from existing stock. Full cash payment is anticipated in Q1 2025. CEO Oleg Vornik commented: “Larger orders of this type from

DroneShield (ASX:DRO) secures $8.2m European defence contract Read More »

Salesforce (ASX:CRM) surges 10% on Q3 results and AI progress

Shares in Salesforce (NYSE: CRM) surged more than 10% in after-hours trading following the release of the company’s fiscal Q3 2025 earnings report. The company exceeded revenue expectations, raised its full-year revenue outlook, and highlighted advancements in its artificial intelligence (AI) initiatives. Shares are currently trading at US$366.30, up from US$331.76 at Tuesday’s close. Salesforce

Salesforce (ASX:CRM) surges 10% on Q3 results and AI progress Read More »

Scroll to Top